<DOC>
	<DOCNO>NCT02956486</DOCNO>
	<brief_summary>The name trial MissionAD1 . This 24-month treatment , multicenter , double-blind , placebo-controlled , parallel group , Phase 3 study participant Early Alzheimer 's Disease ( EAD ) include mild cognitive impairment ( MCI ) due AD/Prodromal AD early stage mild AD conduct evaluate efficacy safety elenbecestat ( propose international nonproprietary name [ INN ] ) ( E2609 ) .</brief_summary>
	<brief_title>A 24-Month Study Evaluate Efficacy Safety E2609 Subjects With Early Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mild cognitive impairment due Alzheimer 's disease ( AD ) mild AD dementia include : 1 . Mini Mental State Examination score equal great 24 2 . Clinical Dementia Rating ( CDR ) global score 0.5 3 . CDR Memory Box score 0.5 great Impaired episodic memory confirm list learn task Positive biomarker brain amyloid pathology indicate either amyloid positron emission tomography ( PET ) cerebrospinal fluid assessment Study partner able support participant duration study Females breastfeed pregnant Screening Baseline . Females childbearing potential must use highly effective method contraception throughout entire study period 28 day study drug discontinuation Any condition may contribute cognitive impairment beyond cause participant 's AD Participants history seizure within 5 year Screening History transient ischemic attack stroke within 12 month Screening Psychiatric diagnosis symptom ( e.g. , hallucination , major depression , delusion , etc . ) â€¢ Suicidal ideation suicidal behavior within 6 month Screening hospitalize treated suicidal behavior past 5 year Have contraindication magnetic resonance imaging ( MRI ) scan Have lesion could indicate dementia diagnosis AD brain MRI Exhibit significant pathological finding brain MRI Participants history moderate severe hepatic impairment ( eg , ChildPugh Class B C ) Results laboratory test conduct Screening outside follow limit : Absolute lymphocyte count LLN Thyroid stimulate hormone normal range Abnormally low Vitamin B12 level Participants risk increase risk infection Have receive live/live attenuate vaccine 3 month randomization Any chronic inflammatory disease adequately control require systemic ocular immunosuppressive immunomodulatory therapy Any clinically significant abnormality Severe visual hearing impairment A prolong QTc interval ( QTcF great 450 millisecond [ m ] ) Malignant neoplasm within 5 year Screening Known suspected history drug alcohol abuse Taking prohibit medication , must review Investigator Have participate recent clinical study Note : Other protocoldefined Inclusion/Exclusion Criteria may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>elenbecestat</keyword>
	<keyword>E2609</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Early Alzheimer 's Disease</keyword>
	<keyword>Prodromal Alzheimer 's Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Dementia , Alzheimer 's type</keyword>
	<keyword>mild cognitive impairment</keyword>
	<keyword>MissionAD1</keyword>
</DOC>